SCHEMBL4560140

SCHEMBL4560140

O=C(Nc1cccc(Br)c1)c1cc[nH]n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.57
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
NPC1 O15118 2/20 0.57
LMNA P02545 1/20 0.57
ALOX15 P16050 1/20 0.57
P2RX1 P51575 1/20 0.51
GRM5 P41594 2/20 0.50
ALDH1A1 P00352 2/20 0.49
TP53 P04637 2/20 0.49
TSHR P16473 1/20 0.49
MAPK1 P28482 1/20 0.49
NLRP3 Q96P20 1/20 0.49
HPGD P15428 1/20 0.49
HTT P42858 1/20 0.48
GAA P10253 1/20 0.48
TGM2 P21980 1/20 0.48
F2 P00734 1/20 0.47
AHR P35869 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30677473 0.82 MEN1 (0.58) RAB9AMEN1KMT2ANPC1LMNA
SCHEMBL6532409 0.81 MGLL (0.55) MEN1KMT2AAHR
SCHEMBL19748 0.81 KMT2A (0.61) RAB9AKMT2ANPC1ALOX15ALDH1A1
SCHEMBL6003890 0.79 GRM4 (0.64) RAB9AMEN1KMT2ANPC1LMNA
SCHEMBL23246073 0.76 GRM4 (0.57) RAB9AMEN1KMT2ANPC1LMNA
SCHEMBL28904211 0.76 GRM4 (0.70) RAB9AMEN1KMT2ANPC1LMNA
SCHEMBL28118358 0.75 KMT2A (0.54) RAB9AKMT2ANPC1ALOX15ALDH1A1
SCHEMBL23246094 0.75 RAB9A (0.55) RAB9AMEN1KMT2ANPC1LMNA
SCHEMBL11039238 0.75 LMNA (0.58) RAB9AMEN1KMT2ANPC1LMNA
SCHEMBL7949522 0.74 PARP1 (0.47) RAB9AMEN1KMT2ANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7589116-B2 Biaryl substituted pyrazoles as sodium channel blockers MERCK & CO. INC. (US) 2009-09-15 US disclosed
EP-1615895-A4 BIARYL SUBSTITUTED PYRAZOLES AS SODIUM CHANNEL BLOCKERS MERCK & CO INC (US) 2007-11-07 EP disclosed
US-20060183785-A1 Biaryl substituted pyrazoles as sodium channel blockers MERCK SHARP & DOHME CORP. 2006-08-17 US disclosed
EP-1615895-A1 BIARYL SUBSTITUTED PYRAZOLES AS SODIUM CHANNEL BLOCKERS Merck & Co., Inc. (US) 2006-01-18 EP disclosed
WO-2004092140-A1 BIARYL SUBSTITUTED PYRAZOLES AS SODIUM CHANNEL BLOCKERS MERCK & CO., INC. (US) 2004-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183785-A1 Biaryl substituted pyrazoles as sodium channel blockers TRPV1, TRPA1, TRPV3 RAB9A 2064/4885MEN1 3928/4885KMT2A 3453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.